BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
74.09
-1.10 (-1.46%)
Feb 5, 2026, 11:04 AM EST - Market open
BridgeBio Pharma Market Cap
BridgeBio Pharma has a market cap or net worth of $14.28 billion as of February 5, 2026. Its market cap has increased by 109.39% in one year.
Market Cap
14.28B
Enterprise Value
15.70B
1-Year Change
109.39%
Ranking
Category
Stock Price
$74.09
Market Cap Chart
Since June 27, 2019, BridgeBio Pharma's market cap has increased from $3.32B to $14.28B, an increase of 330.08%. That is a compound annual growth rate of 24.68%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 4, 2026 | 14.49B | -1.70% |
| Dec 31, 2025 | 14.74B | 184.24% |
| Dec 31, 2024 | 5.19B | -26.16% |
| Dec 29, 2023 | 7.02B | 516.56% |
| Dec 30, 2022 | 1.14B | -53.61% |
| Dec 31, 2021 | 2.46B | -71.83% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 27, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Genmab | 19.54B |
| Revolution Medicines | 18.66B |
| Moderna | 16.71B |
| Roivant Sciences | 15.06B |
| Ionis Pharmaceuticals | 13.77B |
| Ascendis Pharma | 13.49B |
| Exelixis | 11.48B |
| Summit Therapeutics | 11.12B |